Share on StockTwits

Cocrystal Pharma (NASDAQ:COCP) Director Phillip Md Et Al Frost acquired 111,200 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $0.29 per share, for a total transaction of $32,248.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Cocrystal Pharma (NASDAQ:COCP) remained flat at $0.33 during during mid-day trading trading on Wednesday. The stock had a trading volume of 208,147 shares. Cocrystal Pharma has a 52 week low of $0.23 and a 52 week high of $0.97. The stock has a 50-day moving average of $0.29 and a 200-day moving average of $0.42. The company’s market cap is $40.1 million.

Cocrystal Pharma Inc, formerly Biozone Pharmaceuticals, Inc, through its wholly owned subsidiary, BioZone Laboratories, Inc (NASDAQ:COCP), primarily is engaged in the business of developing and manufacturing over the counter (OTC) drug products and cosmetic and beauty products on behalf of third parties.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.